Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PhaseBio Pharmaceuticals, Inc. - Common Stock (NQ: PHAS )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Nov 2, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PhaseBio Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
PhaseBio Announces Interim Analysis of REVERSE-IT Phase 3 Trial Accepted for Late Breaking Science Presentation at the American Heart Association Scientific Sessions 2021
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Appoints William D. Humphries to Board of Directors
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Pharmaceuticals to Present at 23rd Annual H.C. Wainwright Global Investment Conference
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal
Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to... 
Via Talk Markets
PhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of a BLA submission for Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Pharmaceuticals and SFJ Pharmaceuticals® Announce Approval of IND Application in China for Bentracimab
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2021 on July 15
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Midatech Pharma (NASDAQ:MTP) share... 
Via Benzinga
PhaseBio Stock Jumps On Bentracimab Commercialization Pact In Europe
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has entered into an exclusive licensing agreement with privately-held Alfasigma S.p.A for the commercialization of... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Midatech Pharma (NASDAQ:MTP) shares moved upwards by 50.98% to $3.08 during Thursday's pre-market session. The company's market cap stands at $39.0 million... 
Via Benzinga
PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Highlights Real-World Healthcare Cost and Bleeding Cost Data Featured at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Advaxis (NASDAQ:ADXS) shares increased by 27.34% to $0.62 during Wednesday's pre-market session. The company's market cap stands at $85.2 million. Lixte... 
Via Benzinga
PhaseBio Highlights Real-World Bleeding and Surgery Data Featured at The American College of Cardiology's 70th Annual Scientific Session
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Applied DNA Sciences (NASDAQ:APDN) shares rose 27.71% to $7.42 during Tuesday's regular session. Trading volume for Applied DNA Sciences's stock is 7.2... 
Via Benzinga
PhaseBio Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.